Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476567 | 0.84 | MAPK1 (0.35) | MAPK1DRD2MTNR1A | |
| SCHEMBL10829319 | 0.81 | MAPK1 (0.48) | MAPK1DRD2MTNR1AALDH1A1CYP1A2 | |
| SCHEMBL10829944 | 0.78 | MAPK1 (0.42) | MAPK1DRD2MTNR1AALDH1A1KDM4E | |
| SCHEMBL10829330 | 0.77 | MAPK1 (0.50) | MAPK1DRD2MTNR1AALDH1A1CYP1A2 | |
| SCHEMBL25604634 | 0.77 | DRD2 (0.38) | MAPK1DRD2ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL4363300 | 0.72 | PRKAB2 (0.38) | MAPK1DRD2MTNR1AALDH1A1CYP1A2 | |
| SCHEMBL4367785 | 0.72 | PRKAB2 (0.38) | MAPK1DRD2MTNR1AALDH1A1CYP1A2 | |
| SCHEMBL10025493 | 0.71 | MTNR1A (0.34) | DRD2MTNR1A | |
| SCHEMBL24992266 | 0.69 | KDM4E (0.36) | MAPK1DRD2MTNR1AALDH1A1CYP1A2 | |
| SCHEMBL30931199 | 0.69 | KDM4E (0.36) | MAPK1DRD2MTNR1AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085475-A1 | Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9,-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists | WYETH (US) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085475-A1 | Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9,-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists | HTR1A, HTR5A, HTR1B | MAPK1 3707/4885DRD2 224/4885MTNR1A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.